Nouscom demonstrates Preclinical Proof of Concept for Personalized Cancer Neoantigen Vaccine in combination with Immune Checkpoint Blockade to Eradicate Large Tumors

Article published in Nature Communications BASEL, Switzerland – 19 June 2019: Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced [...]

IND for NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine, Cleared by FDA to Commence Clinical Development in MSI Solid Tumors

BASEL, Switzerland – 3rd June 2019: Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that its Investigational New Drug [...]

Nouscom Strengthens Board of Directors with the Appointment of John F. McDonald as an Independent Director

BASEL, Switzerland – 5th November 2018 Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines based on its proprietary technology [...]

ProBioGen and Nouscom Sign License Agreement for ProBioGen’s Technology Platform

Proprietary Duck Cell Line Serves as Large-Scale Production-Suitable Cell Substrate Berlin, Germany, and Basel, Switzerland – June 26th, 2018 ProBioGen AG, a premier German service & [...]

Okairos awarded by Swiss Biotech Association

The Swiss Biotech Association Honors Major Industry Achievements with Swiss Biotech Success Stories Basel, Switzerland, May 04, 2018 — On the occasion of its 20th anniversary, the Swiss [...]

Nouscom’s Neoantigen Vaccine Synergizes with NKTR-214 to Cure Established Tumors in Preclinical Model

Basel, Switzerland – 13 November 2017 Nouscom, an oncology company developing next generation cancer vaccines based on its Exovax platform, today announced preclinical data of its neoantigen [...]

Nouscom raises €42 million Series B financing led by new investor Abingworth with participation from 5AM Ventures, LSP and Versant Ventures

Basel, Switzerland – 6 November 2017 Nouscom, an oncology company developing neoantigen cancer vaccines based on its Exovax platform, today announced the completion of a €42 million Series B [...]

Nouscom appoints new Chief Operating Officer and strengthens the Board of Directors with industry veterans and scientifics experts

Basel, Switzerland – 26 September 2016 Nouscom, an oncology company developing patient specific cancer vaccines based on a clinically validated genetic vaccine platform, today announced the [...]

NousCom concludes successful series A financing of EUR 12 million to support discovery and development of personalized cancer vaccines

Basel, Switzerland – May, 17 2016 Nouscom announced today that it has closed a EUR 12 million Series A financing co-led by LSP and Versant Ventures. The funds will be used to support discovery [...]